ArQule, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

Cowen Group Healthcare Conference 2013

WOBURN, Mass.--()--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013 at 8:00 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes ARQ 087, designed to inhibit fibroblast growth factor receptor, ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.

Contacts

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com

Release Summary

ArQule, Inc. announces presentation at Cowen 33rd Annual Health Care Conference on March 6, 2013.

Contacts

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com